News and Press Releases
Pan Cancer T secures €4.25m in Seed Extension Round to advance next-generation T cell therapies
July 11 2024, Rotterdam, the Netherlands – Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25m Seed...
Category: Drug Delivery
Posted: July 11, 2024
Just – Evotec Biologics selected by US Department of Defence for Manufacturing Optimisation Programme
Just – Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD’s manufacturing optimisation programme Manufacturing solution includes seamless integration of accelerated mAb drug development into...
Category: BioManufacturing
Posted: July 10, 2024
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US
Just – Evotec Biologics expands tech partnership for biosimilars with Sandoz
Just – Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term...
Category: BioManufacturing, Biotechnology
Posted: July 10, 2024
Just – Evotec Biologics, Inc. 401 Terry Avenue North Seattle, WA 98109, US
Concr launches trial using digital twins for outcome prediction in breast cancer
10 July 2024, London United Kingdom – Concr announces that first patients have been recruited to the VISION trial, an observational clinical study evaluating Concr’s therapeutic response predictive algorithm defining...
Category: Biotechnology
Posted: July 10, 2024
Pascal Piedbois MD PhD joins One2Treat as chief medical officer to advance patient-centric innovation in clinical trial design and market access
One2Treat reflects patient priorities in a single multi-facet treatment assessment, reducing trial sample size and accelerating patient access to new treatments. 9 July 2024 -- Brussels, Belgium -- In this...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: July 10, 2024
LSX Nordic Congress Event
LSX Nordic Congress gathers the founders and CEOs of innovative start-ups through to publicly listed healthcare giants, and everyone in between. It represents the breadth and depth of cutting-edge research...
Category:
Posted: July 9, 2024
SciRhom Secures €63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
The upsized and oversubscribed Series A financing round will be used to drive the lead development programme toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary iRhom2...
Category: Drug Discovery, Other, Pharmaceutical
Posted: July 9, 2024
Microbiotica to Present Positive Update on Manufacturing Progress of its Live Biotherapeutic Products for Forthcoming Melanoma and Ulcerative Colitis Clinical Studies
9 July 2024, Cambridge United Kingdom – Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines called live biotherapeutic products (LBPs), announces that Adam Wilkinson, its vice...
Category: BioManufacturing, Drug Discovery
Posted: July 9, 2024
Microbiotica Limited Chesterford Research Park Little Chesterford Cambridge CB10 1XL UK
APEIRON Biologics to be Acquired by Ligand Pharmaceuticals for USD 100 Million
Ligand also commits to invest up to USD 4 million in APEIRON spin-off, invIOs 8 July 2024, Vienna, Austria – APEIRON Biologics AG (“APEIRON”), a leading Austrian biotech company, today...
Category:
Posted: July 8, 2024
Epsilogen announces CTA approval for phase 1b trial of MOv18 IgE in platinum-resistant ovarian cancer
Phase 1b study expected to initiate in H2 2024 Previously reported phase 1 results showed MOv18 IgE to be safe and well-tolerated, with evidence of anti-tumour activity. 8 July 2024...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: July 8, 2024
Spur provides update on FLT201 and planned phase III clinical trial
8 July 2024 -- London, UK -- Syncona Ltd, a leading life science investor focused on creating, building and scaling global leaders in life science, notes that its portfolio company...
Category: Clinical Trials, Other, Pharmaceutical
Posted: July 8, 2024
Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors...
Category: BioManufacturing, Clinical Trials, Other
Posted: July 8, 2024
Myricx Bio Gridiron Building, 1 Pancras Square, King’s Cross, London, N1C 4AG
CSL Behring Announces First Two Patients Treated with HEMGENIX (etranacogene dezaparvovec) Gene Therapy for Haemophilia B in Europe
4 July 2024, Marburg, Germany– Global biotechnology leader CSL Behring (ASX: CSL) today announced that two haemophilia B patients were treated with the gene therapy HEMGENIX (etranacogene dezaparvovec) at Haemophilia...
Category: Pharmaceutical
Posted: July 4, 2024
Sustainability focused PET film producer launches Evercare brand for the healthcare packaging market
18 June 2024 – Evertis launches Evercare brand, set to be a leading provider of specialty and innovative medical-grade films designed to provide superior performance and support regulatory compliance to...
Category: Manufacturing and Packing
Posted: July 3, 2024
Agreement to Explore Optimer Vehicles for Targeted Delivery of siRNA
New Collaboration to Evaluate Aptamer's Fibrotic Liver Delivery Vehicles with siRNA 3 July 2024, York, England - Aptamer Group plc (AIM: APTA), the developer of novel Optimer binders to enable...
Category: Drug Delivery
Posted: July 3, 2024
Aptamer group, Suite 2.80 – 2.87, Bio Centre, Innovation Way, Heslington, York, YO10 5NY
